ACADIA Pharmaceuticals Inc (ACAD) - Total Liabilities
Based on the latest financial reports, ACADIA Pharmaceuticals Inc (ACAD) has total liabilities worth $436.29 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of ACADIA Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
ACADIA Pharmaceuticals Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how ACADIA Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ACADIA Pharmaceuticals Inc (ACAD) total assets.
ACADIA Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of ACADIA Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FLSmidth & Co.
CO:FLS
|
Denmark | Dkr12.38 Billion |
|
EFG International AG
SW:EFGN
|
Switzerland | CHF40.71 Billion |
|
SLM Corp
NASDAQ:SLM
|
USA | $26.10 Billion |
|
Alior Bank S.A.
WAR:ALR
|
Poland | zł94.12 Billion |
|
Chartwell Retirement Residences
TO:CSH-UN
|
Canada | CA$3.33 Billion |
|
New Hope Liuhe Co Ltd
SHE:000876
|
China | CN¥82.46 Billion |
|
Eastern Bankshares Inc
NASDAQ:EBC
|
USA | $26.25 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs13.57 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down ACADIA Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of ACADIA Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACADIA Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACADIA Pharmaceuticals Inc (2000–2025)
The table below shows the annual total liabilities of ACADIA Pharmaceuticals Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $336.81 Million | -25.97% |
| 2024-12-31 | $454.96 Million | +43.43% |
| 2023-12-31 | $317.20 Million | +69.27% |
| 2022-12-31 | $187.40 Million | +17.69% |
| 2021-12-31 | $159.23 Million | +2.33% |
| 2020-12-31 | $155.61 Million | +85.14% |
| 2019-12-31 | $84.05 Million | +37.51% |
| 2018-12-31 | $61.12 Million | +24.18% |
| 2017-12-31 | $49.22 Million | +15.16% |
| 2016-12-31 | $42.74 Million | +93.11% |
| 2015-12-31 | $22.13 Million | +38.61% |
| 2014-12-31 | $15.97 Million | +128.55% |
| 2013-12-31 | $6.99 Million | -70.40% |
| 2012-12-31 | $23.61 Million | +169.72% |
| 2011-12-31 | $8.75 Million | +0.53% |
| 2010-12-31 | $8.71 Million | -76.82% |
| 2009-12-31 | $37.57 Million | +221.49% |
| 2008-12-31 | $11.69 Million | -43.41% |
| 2007-12-31 | $20.65 Million | -7.75% |
| 2006-12-31 | $22.39 Million | -3.24% |
| 2005-12-31 | $23.13 Million | +138.88% |
| 2004-12-31 | $9.68 Million | -88.52% |
| 2003-12-31 | $84.36 Million | +50.35% |
| 2002-12-31 | $56.11 Million | +1269.62% |
| 2001-12-31 | $4.10 Million | -92.76% |
| 2000-12-31 | $56.62 Million | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more